A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases

Clinical Breast Cancer

Volumn 9, Issue 1, 2009, Pages 39-44

  Campos, Susana ^a   Guastalla, Jean Paul ^b   Subar, Milayna ^c   Abreu, Paula ^c   Winer, Eric ^a   Cameron, David ^d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b CENTRE LÉON BÉRARD   (France)

^c PFIZER INC   (United States)

^d WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Aromatase inhibitor; Hormone receptor positive disease; National Cancer Institute Common Toxicity Criteria

Indexed keywords

ANASTROZOLE; EXEMESTANE; ANDROSTANE DERIVATIVE; AROMATASE INHIBITOR; NITRILE; TRIAZOLE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FEVER; HEADACHE; HEART INFARCTION; HOT FLUSH; HUMAN; INSOMNIA; LIMB PAIN; LIVER METASTASIS; LUNG METASTASIS; LYMPHOMA; MAJOR CLINICAL STUDY; NAUSEA; OVERALL SURVIVAL; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; RASH; SHOULDER PAIN; SIDE EFFECT; SOLID TUMOR; SPINAL CORD COMPRESSION; SUDDEN DEATH; THORAX PAIN; TREATMENT DURATION; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; VISCERAL METASTASIS; BRAIN TUMOR; BREAST TUMOR; LIVER TUMOR; LUNG TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; PILOT STUDY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANDROSTADIENES; AROMATASE INHIBITORS; BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; NITRILES; PILOT PROJECTS; POSTMENOPAUSE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; TRIAZOLES;

EID: 65649098606     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2009.n.007     Document Type: Article

References (15)

1. Solomayer EF, Diel IJ, Meyberg GC, et al. Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat 2000; 59:271-8.
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, v.2.2008 January 28, 2008.
3. ARIMIDEX® (anastrozole tablets). Wilmington, DE: Full Prescribing Information, AstraZeneca Pharmaceuticals LP; 2005.
4. AROMASIN® (exemestane). New York, NY: Full Prescribing Information, Pharmacia & Upjohn Co, Division of Pfizer Inc; 2005.
5. Kvinnsland S, Anker G, Dirix LY, et al. High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment. Eur J Cancer 2000; 36:976-82.
6. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000; 18:1399-411.
7. Mauriac L, Pippen JE, Quaresma Albano J, et al. Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. Eur J Cancer 2003; 39:1228-33.
8. Howell A, Buzdar A, Jonat W. Arimidex (anastrozole) -effective in advanced breast cancer (ABC) patients with visceral and liver metastases. Breast Cancer Res Treat 1998; 50:304 (Abstract 434).
9. Steele N, Zekri J, Coleman R, et al. Exemestane in metastatic breast cancer: effective therapy after third-generation non-steroidal aromatase inhibitor failure. Breast 2006; 15:430-6.
10. Jonat W, Howell A, Blomqvist C, et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 1996; 32A:404-12.
11. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-16.
12. Howell A, Robertson JF, Vergote I. A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases. Breast Cancer Res Treat 2003; 82:215-22.
13. Bonneterre J, Buzdar A, Nabholtz JM, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001; 92:2247-58.
14. Miller WR. Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer. Semin Oncol 2003; 30(suppl 14):3-11.
15. Cameron DA, Anderson ED, Levack P, et al. Primary systemic therapy for operable breast cancer-10-year survival data after chemotherapy and hormone therapy. Br J Cancer 1997; 76:1099-105.